Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis October 2, 2025
Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 March 21, 2025
Sitryx Therapeutics Makes Key Sppointments to Dtrengthen Business Operations and Progress Immunometabolism-Targeting Pipeline into Clinical Development March 5, 2024
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases January 4, 2024
Sitryx Announces Partner Lilly Exercises Option to SIT-011 for Chronic AutoImmune and Inflammatory Diseases November 2, 2023
Big Pharma-backed Sitryx Locks an Additional $39M in a Series A Raise to Advance its Immunometabolic Pipeline September 28, 2023
